

Keynote speakers



Prof. Jean-Luc Balligand

UCLouvain

J-L Balligand developed the core of his research projects in the biochemistry and cellular biology of nitric oxide synthases (NOS) including their regulation in cardiovascular tissues.

He initiated the research on the role of NOS in cardiomyocyte contractility which is being extended in the context of myocardial remodelling and regeneration, e.g. in response to catecholamines and beta-adrenoceptors. For this and other work, he received a number of awards, including from the Fonds National de la Recherche Scientifique (Therabel Prize), the Galien Prize and the Vastesaeger Prize of the Belgian Society of Cardiology.

He currently is Head of the Pole of Pharmacology and Therapeutics at the Institut de Recherche Expérimentale et Clinique (IREC), Faculty of Medicine, UC Louvain and member of the Executive Committee, IREC.

He also is practicing Physician at the Cliniques Universitaires Saint-Luc and teaches cardiovascular physiology and pharmacology at the Faculty of Medicine. He is member of the Royal Academy of Medicine of Belgium and Vice-President of the Health competitiveness cluster of the Wallonia Region, BioWin.

Presentation:

- Assistant Professor of Medicine 95, Harvard Medical School
- Agrégation de l'Enseignement Supérieur 97, UC Louvain
- Full Professor of Medicine and Pharmacology 04, UCLouvain(Person) (UCL 1999)

Contact:

balligand@mint.ucl.ac.be

Damien Bertrand

IBA

After a PhD in theoretical physics, **Damien Bertrand** spent two years in academic research on space physics before joining IBA. There he started as R&D physicist working on simulations of the proton therapy system. He has been in charge of the elaboration of collaborative research projects, and became project manager for some of these projects. Recently, he has become Domain Expert for the Hadrontherapy products (particle therapy based on light ion beams).



Contact:

damien.bertrand@iba-group.com



Prof. Koen Debackere

K.U. LEUVEN RESEARCH & DEVELOPMENT

Prof. Dr. Ir. Koenraad Debackere (14.07.1961), has been with K.U. Leuven since 1995. He obtained his Ph.D. in Management with an ICM-fellowship at the University of Ghent after stays as an ICM-fellow and an ICRMOT research assistant at MIT Sloan School of Management. He was a Fulbright-Hays post-doctoral fellow at MIT in 1991-1992. Since 1992 he was for two years an assistant professor at Erasmus University Rotterdam before becoming an NFWO-Post-Doctoral Researcher in 1993. In 1995 he became professor at K.U.Leuven where he teaches Technology and Innovation Management. In 1993, 1995, 1997 and 2008 he has won Best Research Paper Awards from the American Academy of Management and the Decision Sciences Institute.

In 2006 he was awarded the VBO-prize. His research has focused on the area of technology and innovation management and policy, the development of indicators for measuring the linkage between science and technology, the design and use of bibliometric indicators for science policy purposes and the role of entrepreneurial universities in economic development. He has also been an invited professor in the area of Innovation Management in various academic MBA programmes (Manchester Business School, Insead, Milano Politecnico, Tilburg University, Chalmers University). He has been a promotor and recipient of various research grants by IWT (Flanders), FWO (Belgium & Flanders), DWTC (Belgium), EC (European Commission). He is promoter of the Expert Center for R&D Monitoring of the Flemish government at K.U.Leuven.

Since 1999, he is also actively engaged in technology transfer activity as managing director of K.U. Leuven Research & Development and Chairman of the Gemma Frisius Fonds (the venture fund) of the K.U.Leuven. He is the co-founder and chairman of Leuven.Inc, the innovation network of Leuven high-tech entrepreneurs. He is a board member of IWT-Vlaanderen, the Flemish government agency that supports science and technology development in Flemish industry.

Since 2005, he is the general manager of K.U.Leuven.

Contact:

Koenraad.Debackere@econ.kuleuven.be



Jean-Pol Detiffe

DNAVision

Mr Detiffe, 37, is an industrial pharmacist with a diploma in Company Administration (IAG-UCL) and an 'agrégation' in sciences. During the six years preceding the establishment of DNAVision, he held different posts in Quality Assistance. This is a medium sized Contract Research Organisation, a service provider for the pharmaceutical industry, accredited ISO17025, GLP certified and inspected by the FDA. He held posts in Business Development (prospecting the market), was assistant to the Head Pharmacist, responsible for planning and organising the laboratory, writing different documents (expertise reports, user requirements, procedures, quality manual) and developing new lines of biotechnology services. These different positions in the company allowed him to develop expertise in market research and in organisation and management. He acquired wide experience in how different departments of a service provider laboratory function.

In 2003, with the advent and first publication of the human genome, he decided to set up a CRO specialising in genetic analyses for the pharmaceutical industry. After establishing contacts with ULB and IPG on the Gosselies site, **he founded DNAVision** in 2004 with the help of public investors. At the beginning a team of 5 people, DNAVision now has a staff of 35, mainly scientists, whose goal is to make advances in the genomic revolution and in personalised medicine. He is in charge of determining and implementing the strategy of the company, finding partners in industry, negotiating contracts and coordinating communications.

Presentation:

- Pharmacist (UCL 1995),
- Agrégation in Sciences (UCL 1996),
- Master in Business Administration (UCL-IAG 1997),
- Industrial Pharmacist (Qualified Person) (UCL 1999)

Contact:

JP.Detiffe@dnavision.be



France Fannes

BIOWIN

France has a master's degree in medical biology. She started her career as an academic researcher in virology at ULB, before joining Biolab, a Walloon-based company specialised in biomedical diagnostics. During the ten years she spent at Biolab she held various positions as head of R&D, production and marketing. Then, in 1996, she set up BIO ART, a Flanders-based company specialised in the development and production of diagnostic kits. At Bio ART she gained experience in particular in filing patents and negotiating partnership agreements with both small and large-sized biomedical companies. During her time with BIO ART, France was a member of the steering committee of FlandersBio and also become an accredited independent expert to the IWT (the Flemish regional agency for innovation).

Contact:

france.fannes@biowin.org

*“Open innovation –
The New Model to Innovate in Health”*



Sandra Huygen

MDxHealth

Dr. Sandra Huygen started her career in industry in May 2003 by joining an international and publicly listed biotech company called OncoMethylome Sciences recently renamed MDxHealth committed to developing and commercializing advanced molecular diagnostic tests for personalized cancer treatment.

In addition to her assistance in regulatory/compliance issues, Dr. Huygen, who hold a senior management position, assists the team in scientific aspects of collaborative negotiations and relationships. She seeks to optimize the success of the company in basic, translational, and clinical research to encourage synergy and transversal working. Over the last 6 years, her accomplishments were driven by key developed competencies in talent management and management of programmes from strategy to implementation, and therefore their coordination with a quality system approach between the different company departments and internal and external stakeholders such as R&D/technology, business development, marketing, finance, compliance, IP, QA/QS, PR and HR departments. She has also set-up and manage multiple consortium partnerships, and Belgian & European granted programmes, where she has played key negotiation and communication roles by liaising the public and private partners to their respective governments.

Dr. Huygen, earned from the University of Liege (Belgium) a PhD degree in Biomedical & Life Sciences, and an MSc in Cellular and Molecular Biology with a focus on cancer studies and human promoter regulation.

Contact:

sandra.huygen@mdxhealth.com

Jean-Claude Marcourt

WALLOON REGION

Jean-Claude Marcourt in a few dates...

Law degree (licence) from Liège University (1974-1979). Lawyer at the Liège Bar since 1979 (on leave since 1992). Principal private secretary to Guy Mathot, Walloon Minister of Internal Affairs (1992-1994). Principal private secretary to Bernard Anselme, Walloon Minister of Internal Affairs, Civil Service, and the Budget (1994-1995). Principal private secretary to Jean-Claude Van Cauwenberghe, Walloon Minister of the Budget, Finance, Employment, and Training and Minister of the Budget, Finance, and Civil Service of the Government of the French-speaking Community (1995-1997). Principal private secretary to Elio Di Rupo, Deputy Prime Minister and Minister of the Economy and Telecommunications (1998-1999). Principal private secretary to Laurette Onkelinx, Deputy Prime Minister and Minister of Employment (1999-2003). Principal private secretary to Laurette Onkelinx, Deputy Prime Minister and Minister of Justice (2003-2004). Minister of the Economy and Employment of the Walloon Region since July 2004. Minister of the Economy, Employment, Foreign Trade, and Heritage since July 2007. Vice President and Minister of the Economy, SMEs, New Technology, and Foreign Trade since 2009.



Contact:

jeanclaude.marcourt@gov.wallonie.be



Ingrid Maes

PwC

Ingrid Maes (1966) holds a master's degree of Engineering Sciences in Chemistry & Biotechnology (Brussels University). She also attended various post-university courses in management and business.

Ingrid has more than 20 years' experience in the pharma, biotech and life sciences industry and before joining PwC she had several positions at high-tech multinational technology and engineering companies, involved with strategy, innovation and new technology development, and managed worldwide innovative projects in the pharma and life sciences R&D and manufacturing area. Now she is Director at PwC Advisory and responsible for the pharma & life sciences sector for Belgium and business development for the EMEA region. Her key activity areas are: R&D and manufacturing, innovation & technology management, strategy and regulatory compliance.

The last 8 years Ingrid has worked in the field of innovations, new technology evaluation, strategy and scenario planning for pharma and biotech companies.

She is the author of many articles and presentations at international conferences and is involved in various pharma-related organisations, such as the executive committee of ASTM E55 (pharmaceutical manufacturing), MIT's initiative on biopharma futures and the ISPE. She has presented at the inspectors and reviewers training at the FDA in Washington and advised the US government on anticipating the pandemic flu.

Her areas of expertise are:

- Technical and operational due diligence
- Market analysis, business plan development and strategic decision advice in the pharmaceutical and biotech industry
- Future visions and strategies for R&D and manufacturing, innovation & technology management and regulatory compliance

Contact: ingrid.maes@pwc.be

Jean-Marc Nollet

WALLOON REGION

Jean-Marc Nollet comes from Mouscron, where he was born on 7 January 1970.

Today he lives in Fontaine-l'Évêque, near Charleroi, with his wife and three children.

His civic and political commitment began early, and in 1994 he began a five-year term as political secretary of the Ecolo group ("Greens") in the Parliament of the French-speaking Community. He was also Vice-chairman of the public broadcasting company RTBF's Board of Directors from 1995 to 1999.

In 1999 he was appointed Minister of Children's Affairs and Ecolo leader in the Government of the French-speaking Community and remained in these positions until the end of the legislative term in June 2004. His experience in federal government then followed, for in July 2004 he was sworn into the Federal House of Representatives and took on the duties of head of the Ecolo/Groen group – the only bilingual faction in the House. Since July 2009 he has held ministerial positions in both the Walloon Region and French-speaking Community, having been appointed Vice-president of the Walloon Region and the French-speaking Community; Walloon Minister of Sustainable Development, Energy, Housing, and Civil Service; and French-speaking Community Minister of Children's Affairs, Research, and Civil Service.

Jean-Marc Nollet has a licence in political science (with a major in international relations) and is certified to teach upper secondary education (degree of agrégé de l'Enseignement secondaire supérieur).



Presentation:

- Vice-President of Wallonia and the French Community
- Walloon Minister for Sustainable Development and the Civil Service French Community
- Minister for Children, Research and the Civil Service.

Contact:

cabinet@cabinetnollet.be

Prof. Donny Strosberg

SCRIPPS FLORIDA

Donny Strosberg was trained as a Dr. Sc at the Free University of Brussels (ULB), and taught and did research at Harvard University, at University Paris 7 and the Pasteur Institute, and at the Scripps Research Institute in Florida. He published over 360 peer-reviewed original scientific articles and several books, and holds over twenty issued patent families.

He has been an advisor to the pharmaceutical and biotechnology industry for more than 25 years and has started and helped run several biotechnology companies including publicly listed AES-Chemunex, Hybrigenics, Incyte and Praecis, and privately held Biorelix.



More information:

www.donny-strosberg.com

Jean Stéphane

GSK BIOLOGICALS

Jean Stéphane joined the company in 1974 and today is **Chairman and President of GlaxoSmithKline Biologicals the Global Vaccine Division of GSK headquartered in Belgium**. Jean Stéphane was named Baron by King Albert II of the Belgians in 2000 in recognition of his leading contribution to R&D and industry in Belgium. Jean Stéphane has overseen GlaxoSmithKline Biologicals (the company's vaccines business) since 1991, serving as Vice President and General Manager, then Senior Vice President and General Manager, until his appointment as President and General Manager in 1998. Prior to this, he was Vice President of Human Vaccines Research and Development and Production from 1988 to 1991. Jean Stéphane joined the company in 1974 as Head of Bacterial and Viral Vaccines production, becoming Vaccine Production Director in 1980. He served in a variety of capacities as Vaccine Plant Director and R&D Director from 1981 to 1991. Jean received an Engineer in Chemistry and Bio-Industries degree from the University of Gembloux, Belgium, in 1972 and also has a degree in Management from the University of Louvain, Belgium. He has served as President of the Union of French Speaking Companies (1998-2000), is a member of the European Association of Vaccine Producers, and a member of the Management Committee of the Belgian Companies Federation. He is also a member of the Board of several Belgian companies. In November 2007, Jean was elected by the Vaccine Industry CEO's to be their representative on the GAVI Alliance Board and Executive Committee, for a 3 year mandate (starting in June 2008).



Contact:

jean.stephenne@gskbio.com



Contact:

magnus.sjogren@ucb.com

Magnus Sjogren

UCB

Vice President, MD, PhD, Associated Professor **Magnus Sjögren**, (1964) **VP Global Exploratory Development, UCB Pharma, Belgium**, studied Medicine at Linköping Health University in Sweden. After obtaining his MD in 1991, he got his medical license in 1993 and from 1993 to 1999 he trained as Psychiatrist at Sahlgrens University Hospital in Gothenburg Sweden also doing 2 years of Neurology. 1999, the year he became a Specialist in Psychiatry he also completed a PhD-thesis in Clinical Neuroscience. From 1999 to 2003 he was senior Physician at the department for Neuropsychiatry, Gothenburg/Molndal also heading a Neuropsychiatric investigational ward. In 2001 he received a grant from the Medical research Council in Sweden that enabled full time research and in 2002 he became Associate Professor at Gothenburg University, Sweden. In 2003 he joined AstraZeneca as Disease Area Clinical Expert and in 2005 moved to the Netherlands to join Organon N.V. as Director of Clinical Research. He became Senior Director in 2006 and when Schering-Plough acquired Organon, he took on the responsibility as Global Head of Translational Medicine in Schering-Plough. In 2010 he accepted the responsibility as Vice President of Global Exploratory Development in UCB Pharma, Belgium. He has lead several clinical teams and also been project leader for 2 drug development projects, one which was a high priority project. He has been involved in NDA and MAA submissions to EMEA and FDA of Sugamadex®, Asenapine® and supported a resubmission of a new indications for Xyrem®. He has supervised several doctoral students and published more than 110 original scientific articles and an additional 150 abstracts. His interest covers several areas with a main focus in Clinical Neuroscience, Exploratory development and translational medicine. In addition, leadership development and CBT are areas of interest.



Contact:

franck.molina@sysdiag.cnrs.fr

Franck Molina

SysDiag

Since early at the University, Franck Molina has been crossing disciplines from physics, computing sciences to experimental biology. During his PhD he combined experimental biology with biocomputing approaches in order to better understand complex autoimmune disorders. In 1996, he joined Parkes-Davis Company and worked in the Prof. Sir Tom Blundell' group in Cambridge University. There he performs biophysics and biocomputing analyses on MAP Kinases. After, being recruited at CNRS in 1999, he initiated pioneer projects on emerging systems biology and started a new biocomputing group in CNRS Montpellier. His original view on biological processes (functions) modelling was distinguished by the bronze medal from CNRS in 2005. Since 2007, Franck Molina is involved in early developments of synthetic biology applied on health sciences. Next to his academic activities, he experienced around 18 years of close relationships with industrial research. These interactions led to original works patented and under current exploitations. In January 2007, he created SysDiag, a new interdisciplinary lab (math, computing, experimental biology) for complex systems modelling and engineering for the diagnosis mixing academic (CNRS) and industrial (Bio-Rad) forces. Since 2008, he coordinates EUROMEDIAG the south of France cluster in medical diagnosis (Companies, Hospitals and laboratories) member of EUROBIOMED competitiveness cluster.